ESTRO 2025 - Abstract Book

S1339

Clinical - Lung

ESTRO 2025

1890

Digital Poster ADSCaN: A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer. (ISRCTN47674500) matthew QF Hatton 1 , Claire Cantley 2 , corinne Faivre-Finn 3 , Clive Peedell 4 , Anthony Pope 5 , John Fenwick 6 , Rita Simoes 7 , Janette Rawlinson 8 , Debbie rai 2 , elaine McCarney 2 1 Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom. 2 Glasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom. 3 The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom. 4 Clinical Oncology, The JamMiddlesbroughes Cook University Hospital, Middlesbrough, United Kingdom. 5 Clinical Oncology, The Clatterbridge Cancer Centre, Liverpool, United Kingdom. 6 Dept of Physics, The Clatterbridge Cancer Centre, liverpool, United Kingdom. 7 National Radiotherapy Trials Quality Assurance (RTTQA) Group,, Mount Vernon Hospital, london, United Kingdom. 8 ELF LC patient advisory group, WM Cancer Alliance LC EAG, Birmingham, United Kingdom Purpose/Objective: Most patients with stage 3 NSCLC have inoperable disease, comorbidities and poor performance status and are unsuitable for gold-standard concurrent chemo-radiotherapy. The risk of loco-regional relapse is high after sequential chemo-radiotherapy, and therefore there is a rationale for radiotherapy treatment intensification. ADSCaN (REC reference: 16/WS/0165) compared 4 sequential chemo-radiotherapy schedules Material/Methods: Patients with histologically/cytologically confirmed stage-III NSCLC, deemed fit to undertake sequential chemo radiotherapy treatment, were randomised to different radiotherapy schedule after completing 2-4 cycles of platinum-based chemotherapy. Experimental dose-intensified schedules (combining dose escalation and acceleration) included CHART-ED (1) , IDEAL-CRT (2) , I-START (3) and Isotoxic IMRT (4) and were compared to UK-standard sequential chemo-radiotherapy schedule (55Gy in 20 fractions over 4 weeks). The primary endpoint was Progression Free Survival.

Results: Figure I. Progression Free Survival